| Dr Jeff A Brown, MD | |
|
8237 Meadowbridge Rd, Mechanicsville, VA 23116-2329 | |
| (804) 288-1953 | |
| Not Available |
| Full Name | Dr Jeff A Brown |
|---|---|
| Gender | Male |
| Speciality | Vascular Surgery |
| Experience | 35 Years |
| Location | 8237 Meadowbridge Rd, Mechanicsville, Virginia |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1073509634 | NPI | - | NPPES |
| C00105 | Other | VA | PTAN |
| 007305796 | Medicaid | VA |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208600000X | Surgery | 0101047266 (Virginia) | Secondary |
| 2086S0129X | Surgery - Vascular Surgery | 0101047266 (Virginia) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Bon Secours Memorial Regional Medical Center | Mechanicsville, VA | Hospital |
| Rappahannock General Hospital | Kilmarnock, VA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Vascular Surgery Associates Of Richmond Pc | 4385682590 | 16 |
News Archive
A recent meningitis case at Children's National Hospital raises serious concerns about antibiotic resistance in the common bacterium that caused it, researchers from the hospital write in a case report.
Environmental factors are more important than previously thought in understanding the causes of autism, and equally as important as genes, according to the largest study to date to look at how autism runs in families.
Rice University bioengineering students responded to an ophthalmologist's cry for help with a device to diagnose dry eye, the itching and burning sensation that results when a person doesn't produce enough tears or the tears evaporate too quickly.
Vical Incorporated today reported financial results for the quarter ended March 31, 2010. Revenues were $1.5 million for the first quarter of 2010 compared with $2.3 million for the first quarter of 2009, reflecting lower revenues under the company's license agreement with AnGes MG, Inc. Operating expenses were $10.1 million for the first quarter of 2010 compared with $10.6 million for the first quarter of 2009.
Jennerex, Inc. (San Francisco, CA and Ottawa, Ontario), a clinical stage biotherapeutics company developing a proprietary breakthrough product class of targeted oncolytic virus therapeutics, today announced that the European Medicines Agency (EMEA) has granted Orphan Drug Designation to Jennerex's product JX-594 for the treatment of hepatocellular carcinoma (HCC), the most common form of liver cancer. JX-594 is expected to enter a Phase 3 pivotal trial in the second half of 2010.
› Verified 3 days ago
| Entity Name | Vascular Surgery Associates Of Richmond Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1992763742 PECOS PAC ID: 4385682590 Enrollment ID: O20050419000815 |
News Archive
A recent meningitis case at Children's National Hospital raises serious concerns about antibiotic resistance in the common bacterium that caused it, researchers from the hospital write in a case report.
Environmental factors are more important than previously thought in understanding the causes of autism, and equally as important as genes, according to the largest study to date to look at how autism runs in families.
Rice University bioengineering students responded to an ophthalmologist's cry for help with a device to diagnose dry eye, the itching and burning sensation that results when a person doesn't produce enough tears or the tears evaporate too quickly.
Vical Incorporated today reported financial results for the quarter ended March 31, 2010. Revenues were $1.5 million for the first quarter of 2010 compared with $2.3 million for the first quarter of 2009, reflecting lower revenues under the company's license agreement with AnGes MG, Inc. Operating expenses were $10.1 million for the first quarter of 2010 compared with $10.6 million for the first quarter of 2009.
Jennerex, Inc. (San Francisco, CA and Ottawa, Ontario), a clinical stage biotherapeutics company developing a proprietary breakthrough product class of targeted oncolytic virus therapeutics, today announced that the European Medicines Agency (EMEA) has granted Orphan Drug Designation to Jennerex's product JX-594 for the treatment of hepatocellular carcinoma (HCC), the most common form of liver cancer. JX-594 is expected to enter a Phase 3 pivotal trial in the second half of 2010.
› Verified 3 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Jeff A Brown, MD 7900 Shrader Rd, Henrico, VA 23294-4215 Ph: (804) 288-1953 | Dr Jeff A Brown, MD 8237 Meadowbridge Rd, Mechanicsville, VA 23116-2329 Ph: (804) 288-1953 |
News Archive
A recent meningitis case at Children's National Hospital raises serious concerns about antibiotic resistance in the common bacterium that caused it, researchers from the hospital write in a case report.
Environmental factors are more important than previously thought in understanding the causes of autism, and equally as important as genes, according to the largest study to date to look at how autism runs in families.
Rice University bioengineering students responded to an ophthalmologist's cry for help with a device to diagnose dry eye, the itching and burning sensation that results when a person doesn't produce enough tears or the tears evaporate too quickly.
Vical Incorporated today reported financial results for the quarter ended March 31, 2010. Revenues were $1.5 million for the first quarter of 2010 compared with $2.3 million for the first quarter of 2009, reflecting lower revenues under the company's license agreement with AnGes MG, Inc. Operating expenses were $10.1 million for the first quarter of 2010 compared with $10.6 million for the first quarter of 2009.
Jennerex, Inc. (San Francisco, CA and Ottawa, Ontario), a clinical stage biotherapeutics company developing a proprietary breakthrough product class of targeted oncolytic virus therapeutics, today announced that the European Medicines Agency (EMEA) has granted Orphan Drug Designation to Jennerex's product JX-594 for the treatment of hepatocellular carcinoma (HCC), the most common form of liver cancer. JX-594 is expected to enter a Phase 3 pivotal trial in the second half of 2010.
› Verified 3 days ago
Ashleigh Lauren Rapp Hagaman, MD Surgery Medicare: Accepting Medicare Assignments Practice Location: 8262 Atlee Road, Mob 3, Suite 205, Mechanicsville, VA 23116 Phone: 804-559-0194 Fax: 804-417-1427 | |
Michael J Macdougall, MD Surgery Medicare: Accepting Medicare Assignments Practice Location: 8262 Atlee Rd, Suite 205, Mechanicsville, VA 23116 Phone: 804-559-0194 Fax: 804-559-0198 | |
Kathryn Chuquin, Surgery Medicare: Medicare Enrolled Practice Location: 7504 Right Flank Rd, Mechanicsville, VA 23116 Phone: 804-559-3400 | |
George B Newton, MD Surgery Medicare: Accepting Medicare Assignments Practice Location: 8262 Atlee Road, Suite 205, Mechanicsville, VA 23116 Phone: 804-559-0194 Fax: 804-559-0198 | |
John W Snoddy, MD Surgery Medicare: Not Enrolled in Medicare Practice Location: 8262 Atlee Road, Suite 205, Mechanicsville, VA 23116 Phone: 804-559-0194 Fax: 804-559-0198 | |
Dr. Vishnu Ambur, M.D. Surgery Medicare: Accepting Medicare Assignments Practice Location: 8237 Meadowbridge Rd, Mechanicsville, VA 23116 Phone: 804-559-7634 |